Tindupepimut

Dr. Mobasher held several executive roles in industry, most recently CMO at BeiGene IFLI contributed up to $9 million to Enterome’s private funding round in 2025 Enterome has announced a series of encouraging clinical data for OncoMimics™ drug candidates in solid tumors and B-cell lymphomas Paris, France – 29 JANUARY, 2025 Enterome SA , a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies that induce a fast and potent expansion of memory T-cells to fight cancer, has appointed Mehrdad Mobasher, M.D., M.P.H., a hematologist and oncologist and senior biopharmaceutical executive with more than 15 years of leadership experience in global drug development and commercialization, to its Board of Directors. Dr. Mobasher is currently an executive partner at the Institute for Follicular Lymphoma Innovation (IFLI), which is a key investor in Enterome. The company recently announced highly encouraging clinical results with its immune candidate therapies across a range of blood cancers and solid tumors. “IFLI’s highly collaborative support for the development of our OncoMimics™ in vivo immune therapies targeting follicular lymphoma and other forms of B-cell lymphoma has been transformative for Enterome. Dr. Mobasher joining our board further strengthens IFLI’s invaluable support,” said Pierre Belichard, CEO at Enterome. “Enterome has generated promising clinical data in B-cell non-Hodgkin lymphomas, including follicular lymphoma, as well as in selected solid tumors through an entirely new immunotherapy approach. I’m excited to join the Board and work with the leadership team to help translate this innovative science into meaningful outcomes for patients,” said Dr. Mehrdad Mobasher. Dr. Mobasher is a hematologist-oncologist with more than 15 years of leadership experience in drug development. Most recently, he held the position of Chief Medical Officer at BeiGene, leading the hematology portfolio and global launch of zanubrutinib in CLL and follicular lymphoma. Before that, he held roles as Global Head of Oncology Development at Zai Lab, Chief Medical Officer at Corvus Pharmaceuticals, and Group Medical Director at Genentech, where he led the development and launch of several landmark oncology programs including venetoclax and obinutuzumab . In October 2025, Dr. Mobasher was named Executive Partner at IFLI, a global non-profit foundation dedicated to advancing research and treatment for follicular lymphoma. IFLI became an Enterome shareholder when it invested up to $9 million in a $19 million private funding round in June 2025. In December, Enterome presented positive updated Phase 2 interim data from two cohorts of patients with low tumor-burden follicular lymphoma for its lead OncoMimics™ immunotherapy EO2463. The immune therapy candidate also secured FDA Fast Track designation for the watch and wait setting in follicular lymphoma in October. Enterome has also given positive data updates for EO4010 in metastatic colorectal cancer , and for EO2401 in glioblastoma . The Institute for Follicular Lymphoma Innovation (IFLI) is a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). IFLI supports cutting-edge research and technology to lead to the development and commercialization of novel therapeutics and/or biomarkers for the treatment of FL, and to understand the biology of FL. The foundation deploys its budget across research funding, project-based partnerships, and venture philanthropic investments to achieve its innovation goals. IFLI promotes collaboration and works to enable data sharing and the exchange of knowledge and expertise among researchers and institutions advancing FL research. Learn more at . Enterome SA ( ) is a privately held clinical-stage biopharmaceutical company developing breakthrough OncoMimics™ immunotherapeutics for cancer. The three most advanced product candidates have shown positive early data in Phase 2 clinical development, supporting the novel OncoMimics™ modality. The company’s pioneering approach to drug discovery is based on the unique and powerful bacterial Mimicry drug discovery platform, which allows it to discover OncoMimics™ with high similarity to tumor associated antigens (TAA) based on the big-data insights from millions of gut bacterial proteins that live in humans. For more information, please contact: ENTEROME INVESTOR & MEDIA RELATIONS Pierre Belichard Chief Executive Officer +33 (0)1 75 77 27 85 communication@enterome.com Cohesion Bureau Chris Maggos / Giovanni Ca’Zorzi +41 (0)79 367 6254 / +33 (0)7 84 67 07 27 enterome@cohesionbureau.com Attachment 20260129 Enterome PR Mobasher (final)

临床试验病友交流群（点击） 一、新药快讯 1、治疗致命性脑肿瘤，多款创新多肽以及癌症治疗疫苗获得积极临床试验结果。 近日，多肽与寡核苷酸疗法在胶质母细胞瘤（GBM）领域取得了突破。癌症疫苗IGV-001治疗新确诊的胶质母细胞瘤的2b期研究显示，患者的中位总生存期达到20.3个月，较安慰剂组（14.0个月）延长了45%。多肽疗法EO2401结合了三种来源于肠道微生物群中的细菌肽，这些细菌肽与肿瘤中过表达的肿瘤相关抗原相似。EO2401联合PD-1抑制剂纳武利尤单抗±贝伐珠单抗，用于复发胶质母细胞瘤患者的中位总生存时间为14.5个月，术后接受三联方案患者的生存获益更显著。 2、肺癌三代靶向药耐药后新策略，EGFR蛋白降解技术开启全新希望 蛋白降解靶向嵌合体（PROTAC）通过双功能分子一端结合突变EGFR蛋白、另一端招募E3泛素连接酶，引导致癌蛋白降解（而非传统的抑制），可覆盖EGFR基因敏感突变（19del/L858R）及耐药突变（C797X等），这一技术也为三代EGFR靶向药耐药的肺癌患者提供新策略。近日EGFR降解剂BG-60366已在国内获批临床试验，临床前显示BG-60366对奥希替尼的耐药模型有效。该临床研究拟入组使用三代靶向药及含铂化疗失败、携带EGFR耐药突变的晚期非小细胞肺癌患者。 3、新型抗癌药LP-184治疗晚期肿瘤潜力巨大，有晚期肺癌治疗已经2年。 代号为LP-184的靶向药获得了FDA的6项认定（包括快速通道及孤儿药资格），该药在多次经治的晚期实体瘤中展现出了潜力，疾病控制率为54%。22%的患者疾病控制持续超6个月。尤其在对含BRCA1、CHEK2、ATM等DNA损伤修复（DDR）通路缺陷的患者中观察到了持久的疗效，一例BRCA1突变晚期肺癌患者经23个月治疗后靶病灶缩小26%。LP-184为一种前药，依赖肿瘤中高表达的PTGR1酶激活，可选择性引起癌细胞DNA双链断裂，该药的安全性及耐受性良好，将开展针对三阴性乳腺癌、胶质母细胞瘤等疾病的治疗。 二、抗癌前沿 1、分子胶药物正在破解“难以成药”的难题，为诸多晚期癌症患者带来新希望！ 传统的靶向药通过占据靶点的活性口袋来发挥抑制作用，但80%的蛋白缺乏可成药的结合位点。但诱导邻近疗法正突破“难以成药”的靶点局限性，为胰腺癌等难治肿瘤带来新的策略。该模式通过分子胶或双功能分子促使靶点与效应蛋白靠近，利用体内天然通路来调控蛋白功能。分子胶药物（如沙利度胺衍生物）通过招募E3连接酶降解致病蛋白；PROTAC等双功能分子可降解以往不可成药的靶点。代表性进展有RMC-6236治疗RAS突变胰腺癌疾病控制率达92%；蛋白降解靶向嵌合体药物ARV-471上市申请已获FDA受理。 “吉爱3000”惠民检项目，最低2000+可及的基因检测专属福利，全球新药临床试验免费用药、基因检测报告解读，详情微信“长按”下图扫码联系癌度王博进行咨询。 另外，由于微信公众平台的机制调整，恳请各位粉丝朋友花一两秒钟帮我们点亮文章下方的【小手】和【爱心】，这对我们至关重要。谢谢大家！ 点亮小手爱心，送来温暖鼓励